发明名称 Novel pharmaceutical compositions.
摘要 <p>A pharmaceutical preparation containing as active ingredient a compound of the formula &lt;Chemistry id="chema01" num="0001"&gt;&lt;Image id="ia01" he="40" wi="90" file="IMGA0001.TIF" imgContent="chem" imgFormat="TIFF" inline="no" /&gt;&lt;/Chemistry&gt;or a therapeutically acceptable salt thereof in which formula &lt;UnorderedLists id="ula01" listStyle="none"&gt;&lt;ListItem&gt;R' and R&lt;Sup&gt;2&lt;/Sup&gt; are the same or different and each selected from the group consisting of H. CF&lt;Sub&gt;3&lt;/Sub&gt;, NO&lt;Sub&gt;2&lt;/Sub&gt;, -COOCH&lt;Sub&gt;3&lt;/Sub&gt;, -COOC&lt;Sub&gt;2&lt;/Sub&gt;H&lt;Sub&gt;5&lt;/Sub&gt;, alkyl containing 1-7 carbon atoms, halogen, alkoxy, containing 1-5 carbon atoms, and alkanoyl containing 1-4 carbon atoms.&lt;/ListItem&gt;&lt;ListItem&gt;R is selected from the group consisting of H, alkanoyl &lt;!-- EPO &lt;DP n="2"&gt; --&gt;containing 1-4 carbon atoms, and carboalkoxycontaining 2-6 carbon atoms;&lt;/ListItem&gt;&lt;ListItem&gt;and R&lt;Sup&gt;3&lt;/Sup&gt;, R&lt;Sup&gt;4&lt;/Sup&gt; and R&lt;Sup&gt;5&lt;/Sup&gt;, which are the same or different, are each selected from the group consisting of H, CH&lt;Sub&gt;3&lt;/Sub&gt;, C&lt;Sub&gt;2&lt;/Sub&gt;H&lt;Sub&gt;s&lt;/Sub&gt;, OCH&lt;Sub&gt;3&lt;/Sub&gt;, OC&lt;Sub&gt;2&lt;/Sub&gt;H&lt;Sub&gt;5&lt;/Sub&gt;, OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;2&lt;/Sub&gt;OCH&lt;Sub&gt;3&lt;/Sub&gt;, and OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;2&lt;/Sub&gt;OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;3&lt;/Sub&gt;: provided that &lt;UnorderedLists id="ula02" listStyle="none"&gt;&lt;ListItem&gt;a) at least one of R&lt;Sup&gt;3&lt;/Sup&gt;, R&lt;Sup&gt;4&lt;/Sup&gt; and R&lt;Sup&gt;5&lt;/Sup&gt; is selected from the group consisting of CH&lt;Sub&gt;3&lt;/Sub&gt;, C&lt;Sub&gt;2&lt;/Sub&gt;H&lt;Sub&gt;5&lt;/Sub&gt;, OCH&lt;Sub&gt;3&lt;/Sub&gt;, OC&lt;Sub&gt;2&lt;/Sub&gt;H&lt;Sub&gt;5&lt;/Sub&gt;, OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;2&lt;/Sub&gt;OCH&lt;Sub&gt;3&lt;/Sub&gt;, and OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;2&lt;/Sub&gt;OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;3&lt;/Sub&gt;, and&lt;/ListItem&gt;&lt;ListItem&gt;b) when two of R&lt;Sup&gt;3&lt;/Sup&gt;, R&lt;Sup&gt;4&lt;/Sup&gt; and R&lt;Sup&gt;5&lt;/Sup&gt; are H, then the remaining radical R&lt;Sup&gt;3&lt;/Sup&gt;, R&lt;Sup&gt;4&lt;/Sup&gt; or R&lt;Sup&gt;5&lt;/Sup&gt; is selected from the group consisting of OCH&lt;Sub&gt;3&lt;/Sub&gt;, OC&lt;Sub&gt;2&lt;/Sub&gt;H&lt;Sub&gt;5&lt;/Sub&gt;, OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;2&lt;/Sub&gt;OCH&lt;Sub&gt;3&lt;/Sub&gt;. and OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;2&lt;/Sub&gt;OCH&lt;Sub&gt;2&lt;/Sub&gt;CH&lt;Sub&gt;3&lt;/Sub&gt;; the use of the compounds for inhibiting gastric acid secretion; compounds included in the formula 1, and processes for their preparation.&lt;/ListItem&gt;&lt;/UnorderedLists&gt;&lt;/ListItem&gt;&lt;/UnorderedLists&gt;</p>
申请公布号 EP0074341(A1) 申请公布日期 1983.03.16
申请号 EP19820850166 申请日期 1982.08.11
申请人 AKTIEBOLAGET HASSLE 发明人 CARLSSON, ENAR INGEMAR;JUNGGREN, ULF KRISTER;LARSSON, HAKAN SIGURD;VON WITTKEN SUNDELL, GUNHILD WIKA
分类号 A61K31/415;A61K31/44;A61K31/4427;A61P1/04;C07D401/12;(IPC1-7):07D401/12;61K31/44;61K31/415 主分类号 A61K31/415
代理机构 代理人
主权项
地址